Clinical trial
A Phase 2a Study for the Evaluation of Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) as a Vascular Conduit for Coronary Artery Bypass Grafting in Patients With Coronary Artery Disease
NCT07730528 is registered in ClinicalTrials.gov with Humacyte, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Study for the Evaluation of Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) as a Vascular Conduit for Coronary Artery Bypass Grafting in Patients With Coronary Artery Disease
- Lead sponsor
- Humacyte, Inc.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 30, 2026
- Completion date
- September 30, 2030
- Enrollment
- 10 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.